Analysts Set Charles River Laboratories International, Inc. (NYSE:CRL) Target Price at $207.69

Charles River Laboratories International, Inc. (NYSE:CRL) has been assigned an average recommendation of “Moderate Buy” from the sixteen research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $208.50.

A number of research analysts recently weighed in on the stock. UBS Group raised their price target on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Evercore reissued an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Royal Bank Of Canada started coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price for the company. Finally, Barclays increased their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks Research increased its FY2026 EPS estimate for Charles River Laboratories International to $10.91 from $10.79, implying slightly better near-term earnings power.
• Positive Sentiment: The firm also lifted FY2027 EPS forecasts to $12.11 from $11.62 and raised several quarterly estimates, including Q2 2027, Q3 2027, Q4 2027, and Q1 2028, reinforcing a more optimistic longer-term outlook.
• Positive Sentiment: Zacks Research raised Q2 2026, Q3 2026, and Q4 2026 earnings estimates as well, suggesting momentum may be improving across the next several reporting periods.
• Neutral Sentiment: Brokerage sentiment remains constructive overall, with the stock previously noted as having a consensus “Moderate Buy” rating.
• Neutral Sentiment: Recent market commentary also pointed to a 5% share-price surge earlier this week, adding to already positive trading momentum.

Charles River Laboratories International Price Performance

CRL stock opened at $181.06 on Thursday. Charles River Laboratories International has a 1 year low of $132.58 and a 1 year high of $228.88. The stock has a market capitalization of $8.72 billion, a PE ratio of -48.15, a price-to-earnings-growth ratio of 2.07 and a beta of 1.44. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The company’s 50-day moving average is $169.08 and its 200-day moving average is $181.20.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts expect that Charles River Laboratories International will post 11.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. boosted its holdings in Charles River Laboratories International by 84.5% in the 3rd quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock worth $16,384,000 after buying an additional 47,954 shares during the period. Madison Asset Management LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter worth about $1,935,000. JPMorgan Chase & Co. lifted its holdings in Charles River Laboratories International by 14.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock worth $49,626,000 after purchasing an additional 40,073 shares in the last quarter. Penserra Capital Management LLC purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $533,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $1,178,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.